-
公开(公告)号：EP4410378A3
公开(公告)日：2024-10-09
申请号：EP24162480.8
申请日：2017-06-30
IPC分类号： C12N9/22 , A61K38/46 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P9/00 , A61P15/00 , A61P17/00 , A61P21/00 , A61P25/00 , A61P27/00 , A61P29/00 , A61P31/04 , A61P37/02
CPC分类号： C12Y301/21001 , C07K2317/7220130101 , C07K2319/3020130101 , C12Y301/27005 , A61K38/00 , C12N9/22 , A61P1/00 , A61P1/04 , A61P1/16 , A61P15/00 , A61P17/00 , A61P19/02 , A61P21/00 , A61P25/00 , A61P27/02 , A61P29/00 , A61P31/04 , A61P3/10 , A61P37/02 , A61P7/00 , A61P7/06 , A61P9/00
摘要： The invention provides for optimized binuclease fusion proteins with increased pharmacokinetic properties. The optimized binuclease fusion proteins of the invention two or more nuclease domains (e.g., RNase and DNase domain) operably coupled to an Fc domain. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.
-
公开(公告)号：EP4434589A2
公开(公告)日：2024-09-25
申请号：EP24157472.2
申请日：2016-10-22
发明人： LIU, David R. , HU, Johnny Hao
IPC分类号： A61P43/00
CPC分类号： C07K14/32 , C07K2319/0020130101 , C07K2319/0920130101 , C07K2319/8020130101 , C12N9/22 , C12N9/78 , C12Y305/04005 , C12N9/2497 , A61P13/02 , A61P13/12 , A61P17/00 , A61P19/02 , A61P21/00 , A61P21/02 , A61P25/00 , A61P25/28 , A61P29/00 , A61P3/00 , A61P31/12 , A61P31/18 , A61P35/00 , A61P43/00 , A61P7/04 , A61P9/00
摘要： Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for engineering Cas9 and Cas9 variants that have increased activity on target sequences that do not contain the canonical PAM sequence. In some embodiments, fusion proteins comprising such Cas9 variants and nucleic acid editing domains, e.g., deaminase domains, are provided.
-
公开(公告)号：EP4426356A1
公开(公告)日：2024-09-11
申请号：EP22888561.2
申请日：2022-10-31
发明人： WEEDEN, Timothy , VIEIRA, Benjamin , DESJARDINS, Cody, A. , SUBRAMANIAN, Romesh, R. , QATANANI, Mohammed, T. , QUINN, Brendan , NAJIM, John , SHEN, Peiyi
CPC分类号： A61P21/00 , C07K2317/5620130101 , C07K2317/56520130101 , C07K16/2881 , C07K2317/5520130101 , A61K47/6807 , A61K47/6849 , A61K47/6889
-
公开(公告)号：EP4406601A3
公开(公告)日：2024-09-11
申请号：EP24163334.6
申请日：2017-12-14
CPC分类号： A61K47/645 , A61P21/00
摘要： Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 45 skipping are described.
-
-
公开(公告)号：EP3632453B1
公开(公告)日：2024-09-04
申请号：EP18805833.3
申请日：2018-05-25
IPC分类号： A61K35/74 , A61K35/742 , A61P21/00
CPC分类号： A61K35/742 , A61P21/00 , A23K10/16 , A23K50/75
-
公开(公告)号：EP3617195B1
公开(公告)日：2024-08-28
申请号：EP18790125.1
申请日：2018-04-25
IPC分类号： C07D215/44 , C07C271/24 , C07D213/75 , C07D213/81 , C07D213/84 , C07D401/04 , C07D405/04 , C07D405/14 , C07D413/12 , C07D417/04 , A61P35/00
CPC分类号： C07C215/44 , A61P1/16 , A61P1/02 , A61P31/00 , A61P3/06 , A61P3/04 , A61P1/00 , A61P21/02 , A61P25/00 , A61P13/02 , A61P11/00 , A61P37/06 , A61P25/24 , A61P15/00 , A61P29/02 , A61P13/10 , A61P25/04 , A61P25/16 , A61P25/20 , A61P21/00 , A61P9/06 , A61P9/00 , A61P25/28 , A61P29/00 , A61P35/00 , A61P5/14 , A61P35/02 , A61P19/10 , A61P1/18 , A61P37/00 , A61P13/08 , A61P31/18 , A61P11/04 , A61P17/00 , A61P13/12 , A61P11/06 , A61P11/02 , A61P1/04 , A61P19/02 , A61P43/00 , A61P7/00 , A61P9/12 , A61P25/08 , A61P3/10 , C07C271/24 , C07C2602/1020170501 , C07D213/75 , C07B2200/0720130101 , C07D401/04 , C07D213/84 , C07D405/04 , C07D405/14 , C07D213/81 , C07D413/12 , C07D417/04
-
公开(公告)号：EP3303386B1
公开(公告)日：2024-08-28
申请号：EP16728559.2
申请日：2016-06-02
-
9.发明公开
公开(公告)号：EP4414037A3
公开(公告)日：2024-08-21
申请号：EP24165019.1
申请日：2017-09-15
发明人： NAGASE, Hiroshi , FUJII, Hideaki , SAITOH, Akiyoshi , NAKATA, Eriko , HIROSE, Masaaki , OOI, Isao , HAYASHIDA, Kohei
IPC分类号： A61K31/485 , A61K31/439 , A61K31/444 , A61K31/4709 , A61K31/497 , A61K31/501 , A61K31/506 , A61P21/00 , A61P25/04 , A61P25/06 , A61P25/22 , A61P25/24 , A61P43/00
CPC分类号： A61K31/439 , A61K31/444 , A61K31/4709 , A61K31/497 , A61K31/501 , A61K31/506 , A61P25/24 , A61P25/04 , A61P21/00 , A61P25/22 , A61P25/06 , A61P43/00 , A61K31/485
摘要： The present invention relates to a pharmaceutical composition comprising a morphinan derivative that exhibits an opioid δ receptor agonist activity. By administering the pharmaceutical composition provided by the present invention, opioid δ receptor-related diseases (for example, a depression as a symptom associated with Alzheimer's disease) can be treated or prevented.
-
公开(公告)号：EP4410296A1
公开(公告)日：2024-08-07
申请号：EP22875183.0
申请日：2022-09-30
发明人： ZHOU, Haibo , HU, Xinde , SU, Jinlin
IPC分类号： A61K31/713 , A61K31/551 , C07K14/47 , C12N15/113 , A61P25/00
CPC分类号： A61K31/551 , A61K31/7088 , A61K31/713 , A61K45/00 , A61K48/00 , A61P9/10 , A61P21/00 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/28 , A61P27/02 , A61P25/00 , A61P27/16 , A61P27/06 , C07K14/47 , C12N15/113
摘要： Provided are an RE1/NRSE element as a target for transdifferentiation of non-neuronal cells into neuronal cells, and the use of an RE1/NRSE blocker in the prevention and/or treatment of diseases associated with loss of function or death of neurons. Also provided is a method for blocking an RE1/NRSE element so as to regulate the expression of a neuron-associated gene in non-neuronal cells. The method comprises reducing binding of REST to an RE1/NRSE element or reducing the amount or activity of REST. Also provided is an RE1/NRSE element blocker, particularly a binding structural domain of an endogenous RE1/NRSE binding protein and a variant thereof, which can be used for the prevention and/or treatment of diseases associated with loss of function or death of neurons.
-
-
-
-
-
-
-
-
-
搜索结果
322 条记录 (耗时 0.027 秒)
